Hemogenyx Pharmaceuticals Plc · LSE:HEMO
Hemogenyx Pharmaceuticals — Investor Presentation (May 2026)
24 slides from Hemogenyx Pharmaceuticals's investor presentation, May 2026
Slide 1: Delivering Breakthrough Therapies for the Treatment of Blood Diseases
DELIVERING BREAKTHROUGH THERAPIES FOR THE TREATMENT OF BLOOD DISEASES
Slide 2: Disclaimer Notice
Disclaimer Notice The information described in this presentation is information that is confidential, price- This presentation is issued on behalf of Hemogenyx Pharmaceuticals plc (the “Company”) sensitive and which has not been publicly disclosed. By your receipt of solely for the purposes of preli
Slide 3: Company Overview
Company Overview ▪ Hemogenyx Pharmaceuticals: A Clinical Stage Drug Development Company Targeting Unmet Needs in AML, ALL, and Oncology with Three Groups Of Product Candidates: o HG-CT-1: A proprietary, next-generation CAR-T therapy developed to provide a more effective and safer treatment for adult
Slide 4: Pipeline Overview
Pipeline Overview Lead IND Enabling Modality Program Target Indication Discovery Phase 1 Phase 2 Optimisation studies R/R AML HG-CT-1 FLT3 adults R/R AML, HG-CT-1 FLT3 pediatric Cell Therapy HG-CT-1 FLT3 ALL CBR Undisclosed GBM CBR Undisclosed R/R NHL R/R Multiple CBR Undisclosed Myeloma IND-enablin
Slide 5: Leadership Team
Leadership Team Sir Marc Feldmann Vladislav Sandler, PhD Chairman Chief Executive Officer, Co-Founder ■ Medicine and PhD in Immunology from the Walter ■ Widely published stem cell scientist with decades and Eliza Hall Institute of Medical Research of experience in scientific research at world leadin
Slide 6: Scientific, Clinical, Business Advisors and Team Principals
Scientific, Clinical, Business Advisors and Team Principals H. Michael Shepard, PhD Koen van Besien, MD Alan Walts, PhD ■ PhD in Cellular Molecular Developmental ■ Professor of Medicine and Director of ■ Venture Partner at Advent Life Sciences, Biology the Stem Cell Transplant Program at the Directo
Slide 7: AML Market, Treatment Paradigm, Unmet Need
AML Market, Treatment Paradigm, Unmet Need Estimated 61,090 cases of leukemia 20,240 new cases of AML AML diagnosed in the US in 2021* diagnosed in the US in 2021* Front-line Therapy r/r AML is Almost Universally Fatal Remission 30% Relapsed Refractory 70% Consolidation Therapy ▪ Most patients lack
Slide 8: CAR-T program for treatment of relapsed/refractory Acute Myeloid Leukemia
CAR-T program for treatment of relapsed/refractory Acute Myeloid Leukemia
Slide 9: HG-CT-1: a novel CAR-T therapy for AML
HG-CT-1: a novel CAR-T therapy for AML Autologous 3 rd generation CAR-T therapies: CAR-T mediated cytotoxicity ▪ Mechanism of Action: cytotoxic T lymphocyte (CTL)-mediated cytolysis Perforin and Granzyme ▪ Clinically proven safety 1 Cytotoxic CAR-T FLT3+ cell ▪ Established Freedom to Operate FLT3 HG
Slide 10: HG-CT-1: an Autologous CAR-T Therapy; Manufacturing
HG-CT-1: an Autologous CAR-T Therapy; Manufacturing Manufacturing Process Lead IND Enabling Modality Area Program Target Indication Discovery Phase 1 Phase 2 Optimisation studies R/R AML IND opened in Q1 2024 Cell Therapy Oncology HG-CT-1 FLT3 Completed (adults) Phase I initiated in H1 2025 R/R AML
Slide 11: HG-CT-1: Clinical Development Strategy
HG-CT-1: Clinical Development Strategy Development Goal – Cure patients suffering from R/R AML Phase I trial 12-18 months ▪ For adult patients with R/R AML ▪ Clinical development initiated at MD Anderson Cancer Center (MDA) ▪ For pediatric patients with R/R AML ▪ PI of the study is Dr. Nicholas Shor
Slide 12: Phase 1 Study of HG-CT-1 in Adults and Children with R/R AML
Phase 1 Study of HG-CT-1 in Adults and Children with Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML) Designed to establish safety and early signal in a high-mortality AML population with limited treatment options Initial data validate safety, feasibility, and early activity supporting continu
Slide 13: HG-CT-1 – Clinical Plan
HG-CT-1 – Clinical Plan Activity Year 1 Year 2 Year 3 Year 4 Year 5 Phase I (adults): ▪ Safety ▪ Potential efficacy Phase I (pediatric) ▪ Safety ▪ Potential efficacy Phase II (adults) ▪ Efficacy Registration/Phase III ▪ Duration of response in evaluable subjects who achieve a response Registration/P
Slide 14: CDX program for treatment of relapsed/refractory Acute Myeloid Leukemia
CDX program for treatment of relapsed/refractory Acute Myeloid Leukemia
Slide 15: CDX: a Novel Humanized FLT3-CD3 Bispecific Antibody
CDX: a Novel Humanized FLT3-CD3 Bispecific Antibody ▪ An “off the shelf” (non patient-specific) product ▪ Eliminates AML-derived cells transplanted into humanized mice and conditions humanized mouse bone marrow in vivo ▪ High affinity binding to FLT3 ▪ No FLT3 Ligand (FLT3L) competition 1 ▪ Unique b
Slide 16: CDX: Potential Path to IND and Clinical Plan
CDX: Potential Path to IND and Clinical Plan Activity Year 1 Year2 Preclinical ADME/toxicology studies Rhesus monkeys (cross-reactive species) to demonstrate: • Safety • Potential for functional activity (elimination of HSC/HP) Establishment of master cell line, process development and formulation P
Slide 17: Chimeric Bait Receptor Platform
Chimeric Bait Receptor Platform
Slide 18: CBR Program
CBR Program A novel paradigm for targeting Cancer, Neurodegenerative disease treatments and creating Antivirals Mechanism of action: Programming or redirection of myeloid immune cells such as macrophage using novel synthetic proteins Expected significant advantages: As CBR-programmed macrophages: a.
Slide 19: Synthetic Macrophage Receptors - Design Concepts
Synthetic Macrophage Receptors - Design Concepts Cell Therapy Biologics Malignancy Malignancy MACROPHAGE MACROPHAGE Infection Infection Viral Viral 19
Slide 20: Intellectual Property
° “80 HEMOGENYX see PHARMACEUTICALS oe e a life saving company Intellectual Property
Slide 21: Intellectual Property Position
Intellectual Property Position ▪ Hemogenyx has a strong Intellectual Property position and know-how ▪ Patents cover compositions of matter and methods of use for the CAR-T and CDX programs, in major jurisdictions ▪ In addition, other granted US patents are: o “Method of eliminating hematopoietic ste
Slide 22: Company Foundation
Company Foundation Our Mission: A Focus on Solutions Not Just Technology The Power of Self-Selected Team From day one, Hemogenyx Pharmaceuticals was founded with a clear While my expertise laid the foundation for the company, our ability to generate purpose: transformative ideas and translate them i
Slide 23: Summary
Summary Advancing product candidates towards the clinic ▪ HG-CT-1 therapy for the treatment of relapsed/refractory AML and subset of ALL in adults and pediatric patients; IND cleared by US FDA and Phase I trial is initiated, first patient treated, second patient consented. ▪ CDX bi-specific antibody
Slide 24: Thank You!
Thank You! Contact information: Hemogenyx Pharmaceuticals Vladislav Sandler, Ph.D. Co-founder and CEO vladislav.sandler@hemogenyx.com +1 (347) 735-8380
Hemogenyx Pharmaceuticals — Investor Presentation (May 2026) on 6ix